Polyamine metabolism in gliomas

Journal of Neuro-Oncology

Volumn 29, Issue 2, 1996, Pages 167-174

  Ernestus, Ralf Ingo ^a   Röhn, Gabriele ^a   Schröder, Roland ^a   Els, Thomas ^b   Lee, Jin Yul ^a   Klug, Norfrid ^a   Paschen, Wulf ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Brain tumours; Gliomas; Grading; Ornithine decarboxylase (ODC); Polyamines

Indexed keywords

ORNITHINE DECARBOXYLASE; POLYAMINE; PUTRESCINE; SPERMIDINE; SPERMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER GRADING; CHILD; ENZYME ACTIVITY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; POLYAMINE METABOLISM;

EID: 0030054744     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00182140     Document Type: Article

References (48)

1. Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243: C212-C221, 1982
2. Shimizu H, Kakimoto Y, Sano I: The determination and distribution of polyamines in mammalian nervous system. J Pharmacol Exp Ther 143: 199-204, 1964
3. Kremzner LT, Barrett RE, Terrano MJ: Polyamine metabolism in the central and peripheral nervous system. Ann NY Acad Sci 171: 735-748, 1970
4. Seiler N: Polyamine metabolism and function in the brain. Neurochem Int 3: 95-110, 1981
5. Canellakis ES, Viceps-Madore D, Kyriakidis DA, Heller JS: The regulation and function of ornithine decarboxylase and of the polyamines. Curr Top Cell Regul 15: 155-202, 1979
6. Williams-Ashman HG, Canellakis ZN: Polyamines in mammalian biology and medicine. Perspect Med 22: 421-438, 1979
7. Heby O: Role of polyamines in the control of cell proliferation and differentiation. Differentiation 19: 1-20, 1981
8. Bachrach U: Polyamines as chemical markers of malignancy. Ital J Biochem 25: 77-93, 1976
9. Jänne J, Pösö H, Raina A: Polyamines in rapid growth and cancer. Biochem Biophys Acta 473: 241-293, 1978
10. Horn Y, Beal SL, Walach N, Lubich WP, Spigel L, Marton LJ: Further evidence for the use of polyamines as biochemical markers for malignant tumors. Cancer Res 42: 3248-3251, 1982
11. Cohen SS: Conference on polyamines in cancer. Cancer Res 37: 939-942, 1977
12. Russell DH: Clinical relevance of polyamines. Crit Rev Clin Lab Sci 18: 261-311, 1983
13. Ernestus R-I, Röhn G, Hossmann K-A, Paschen W: Polyamine metabolism in experimental brain tumors of rat. J Neurochem 60: 417-422, 1993
14. Scalabrino G, Ferioli ME: Degree of enhancement of polyamine biosynthetic decarboxylase activities in human tumors: A useful new index of degree of malignancy. Cancer Detect Prev 8: 11-16, 1985
15. Ernestus R-I, Röhn G, Schröder R, Klug N, Hossmann K-A, Paschen W: Activity of ornithine decarboxylase (ODC) and polyamine levels as biochemical markers of malignancy in human brain tumors. Acta Histochem (Suppl) 42: 159-164, 1992
16. Harik SI, Sutton CH: Putrescine as a biochemical marker of malignant brain tumors. Cancer Res 39: 5010-5015, 1979
17. Mirzoian RA, Promyslov MSH: Putrescine and polyamines in human and rat brain gliomas. Ukr Biochim Zh 51: 474-476, 1979
18. Moulinoux J-P, Quemener V, Le Calve M, Chatel M, Darcel F: Polyamines in human brain tumors. A correlative study between tumor, cerebrospinal fluid and red blood cell free polyamine levels. J Neuro-Oncol 2: 153-158, 1984
19. Goldman SS, Volkow ND, Brodie J, Flamm ES: Putrescine metabolism in human brain tumors. J Neuro-Oncol 4: 23-29, 1986
20. Kurihara H, Matsuzaki S, Yamazaki H, Tsukahara T, Tamura M: Relationship between tissue polyamine levels and malignancy in primary brain tumors. Neurosurgery 32: 372-375, 1993
21. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumours of the central nervous system, 2nd ed. Springer, Berlin, Heidelberg, New York, 1993
22. Paschen W, Röhn G, Meese CO, Djuricic B, Schmidt-Kastner R: Polyamine metabolism in reversible cerebral ischemia: Effect of α-difluoromethylornithine. Brain Res 453: 9-16, 1988
23. Djuricic BM, Paschen W, Schmidt-Kastner R: Polyamines in the brain: HPLC analysis and its application in cerebral ischemia. Yugoslav Physiol Pharmacol Acta 24: 9-17, 1988
24. Dienel GA, Cruz NF: Induction of brain ornithine decarboxylase during recovery from metabolic, mechanical, thermal, or chemical injury. J Neurochem 42: 1053-1061, 1984
25. Ali SF, Newport GD, Slikker W, Bondy SC: Effect of trimethyltin on ornithine decarboxylase in various regions of the mouse brain. Toxicol Lett 36: 67-72, 1987
26. Russell DH: Ornithine decarboxylase as a biological and pharmacological tool. Pharmacology 20: 117-129, 1980
27. Slotkin TA, Bartolome J: Role of ornithine decarboxylase and the polyamines in nervous system development: A review. Brain Res Bull 17: 307-320, 1986
28. Dorn A, Müller M, Bernstein H-G, Pajunen A, Järvinen M: Immunohistochemical localization of L-ornithine decarboxylase in developing rat brain. Int J Dev Neurosci 5: 145-150, 1987
29. Russell DH, Haddox MK: Cyclic AMP-mediated induction of ornithine decarboxylase in normal and neoplastic growth. Adv Enzyme Regul 17: 61-79, 1978
30. Endo Y, Matsushima K, Onozaki K, Oppenheim JJ: Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor. J Immunol 141: 2342-2348, 1988
31. Pegg AE: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48: 759-774, 1988
32. Grens A, Scheffler IE: The 5′- and 3′-untranslated regions of ornithine decarboxylase mRNA affect the translational efficiency. J Biol Chem 265: 11810-11816, 1990
33. Gilmour SK, Robertson FM, Megosh L, O'Connell SM, Mitchell J, O'Brien TG: Induction of ornithine decarboxylase in specific subpopulations of murine epidermal cells following multiple exposures to 12-O-tetradecanoylphorbol-13-acetate, merzerein and ethyl phenylpropriolate. Carcinogenesis (Lond) 13: 51-56, 1992
34. Hill JR, Morris DR: Cell-specific translation of S-adenosylmethionine decarboxylase mRNA. J Biol Chem 267: 21886-21893, 1992
35. McCann PP, Pegg AE: Ornithine decarboxylase as an enzyme target for therapy. Pharmocol Ther 54: 195-215, 1992
36. Lövkvist E, Stjernborg L, Persson L: Feedback regulation of mammalian ornithine decarboxylase studies using a transient expression system. Eur J Biochem 215: 753-759, 1993
37. Shantz LM, Pegg AE: Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 54: 2313-2316, 1994
38. Hoshino T, Nomura K, Wilson CB, Knebel KD, Gray JW: The distribution of nuclear DNA from human brain-tumor cells. J Neurosurg 49: 13-21, 1978
39. Bigner DD: Biology of gliomas: Potential clinical implications of glioma cellular heterogeneity. Neurosurgery 9: 320-326, 1981
40. Berkman RA, Clark WC, Saxena A, Robertson JT, Oldfield EH, Ali IU: Clonal composition of glioblastoma multiforme. J Neurosurg 77: 432-437, 1992
41. Reifenberger G, Deckert M, Wechsler W: Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors. Acta Neuropathol (Berl) 78: 166-175, 1989
42. Deckert M, Reifenberger G, Wechsler W: Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 115: 179-188, 1989
43. Coons SW, Johnson PC: Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 52: 609-618, 1993
44. Allegranza A, Girlando S, Arrigoni GL, Veronese S, Mauri FA, Gambacorta M, Pollo B, Dalla Palma P, Barbareschi M: Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch [A] 419: 417-423, 1991
45. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992
46. Stavrou D, Bise K, Groeneveld J, Socker U, Kretzschmar HA, Keiditsch E, Mehrain P: Antigenic heterogeneity of human brain tumors defined by monoclonal antibodies. Anticancer Res 9: 1489-1496, 1989
47. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, Kimmel DW: Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 74: 920-927, 1994
48. Glantz MJ, Burger PC, Herndon II JE, Friedman AH, Cairncross JC, Vick NA, Schold Jr SC: Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 41: 1741-1744, 1991